- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06332781
Intravesical Gentamicin to Prevent Recurrent UTI
March 26, 2024 updated by: Women and Infants Hospital of Rhode Island
Feasibility assessment of intravesical gentamicin instillation (putting antibiotics directly into the bladder) versus the current standard of care of oral nitrofurantoin prophylaxis (taking a low dose of antibiotics by mouth every day) to prevent recurrent urinary tract infections (UTI)
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
The overall goal of this project is to assess the feasibility of a larger trial investigating the use of intravesical gentamicin instillation (putting antibiotics directly into the bladder) versus the current standard of care of oral nitrofurantoin prophylaxis (taking a low dose of antibiotics by mouth every day).
Investigators plan to gain patient perspective regarding preferences for study design and assess associations between the treatments with changes in the postmenopausal urinary microbiome (urobiome).
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion criteria:
- Postmenopausal
- 2 UTIs in 6 months
- desire to start antibiotic prophylaxis to prevent UTIs
Exclusion criteria:
- Parkinsons disease
- myasthenia gravis
- renal failure
- liver failure
- bladder pain syndrome
- multiple negative urine cultures associated with UTI symptoms (>/= 3)
- bladder Botox treatments in the past
- treatment planned for UI and prolapse
- unevaluated microscopic hematuria
- history of kidney stones
- most recent weight <40kg (88.18lbs)
- surgically altered urinary tract (urinary diversion, phalloplasty, etc)
- allergy or hypersensitivity to either of the study medications or medications in the same family including but not limited to: amikacin, kanamycin, neomycin, paromomycin, streptomycin, tobramycin.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard of Care
Standard of care
|
administered PO
|
Experimental: Experimental
Gentamicin
|
administered via bladder
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
UTIs
Time Frame: 3 months, 6 months
|
culture-proven UTIs
|
3 months, 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient reported outcome measures
Time Frame: 3 months, 6 months
|
UTI Symptom Assessment
|
3 months, 6 months
|
Patient reported outcome measures
Time Frame: 3 months, 6 months
|
recurrent UTI symptom scale
|
3 months, 6 months
|
Patient reported outcome measures
Time Frame: 3 months, 6 months
|
recurrent UTI impact questionaire
|
3 months, 6 months
|
Patient reported outcome measures
Time Frame: 3 months, 6 months
|
short-form-36
|
3 months, 6 months
|
Patient reported outcome measures
Time Frame: 3 months, 6 months
|
general anxiety disorder-7
|
3 months, 6 months
|
Patient reported outcome measures
Time Frame: 3 months, 6 months
|
patient health questionnaire
|
3 months, 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
urobiome analysis
Time Frame: 3 months, 6 months
|
bacterial presence
|
3 months, 6 months
|
urobiome analysis
Time Frame: 3 months, 6 months
|
antimicrobial resistance gene presence
|
3 months, 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
August 1, 2024
Primary Completion (Estimated)
June 1, 2025
Study Completion (Estimated)
July 31, 2025
Study Registration Dates
First Submitted
December 13, 2023
First Submitted That Met QC Criteria
March 19, 2024
First Posted (Actual)
March 27, 2024
Study Record Updates
Last Update Posted (Actual)
March 28, 2024
Last Update Submitted That Met QC Criteria
March 26, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Urologic Diseases
- Disease Attributes
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Recurrence
- Urinary Tract Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Anti-Infective Agents, Urinary
- Gentamicins
- Nitrofurantoin
Other Study ID Numbers
- 2126175
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Uti
-
Nationwide Children's HospitalThrasher Research FundCompletedCatheter-Related Infections | Recurrent UTIsUnited States
-
Queen's UniversityActive, not recruiting
-
TriHealth Inc.Active, not recruiting
-
Silq Technologies CorporationActive, not recruiting
-
Ann & Robert H Lurie Children's Hospital of ChicagoRecruitingRecurrent UtiUnited States
-
Washington University School of MedicineWithdrawnUTI | Female Urogenital Diseases | UTI - Lower Urinary Tract Infection
-
Ochsner Health SystemProcter and GambleCompletedUrinary Tract Infections | Antibiotic Resistant Infection | Recurrent UTIUnited States
-
Assaf-Harofeh Medical CenterCompletedHematuria | Recurrent Uti | DysuriaIsrael
-
Lawson Health Research InstituteSt. Joseph's Health Care London; Urobiome TherapeuticsTerminatedUrinary Tract Infections | UTI | UTI - Lower Urinary Tract InfectionCanada
Clinical Trials on Nitrofurantoin
-
Ranbaxy Laboratories LimitedCompleted
-
HaEmek Medical Center, IsraelClalit Health ServicesWithdrawn
-
University Hospital, GenevaEuropean CommissionUnknownCystitis | Urinary Tract InfectionsIsrael, Poland, Switzerland
-
Paratek Pharmaceuticals IncCompletedCystitis | Uncomplicated Urinary Tract InfectionUnited States
-
Mylan Pharmaceuticals IncCompleted
-
Wake Forest University Health SciencesCompletedCatheter-Associated Urinary Tract InfectionUnited States
-
St. Jude Children's Research HospitalParexel; Jazz PharmaceuticalsCompletedAcute Lymphoblastic Leukemia | Non Hodgkins LymphomaUnited States
-
Altamash Institute of Dental MedicineCompletedPain, Postoperative | Irreversible PulpitisPakistan
-
Brigham and Women's HospitalTheralogix LLCActive, not recruitingUrinary Incontinence | Pelvic Organ Prolapse | Urinary Tract InfectionsUnited States
-
Mylan Pharmaceuticals IncCompletedHealthyUnited States